Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Sensorion    ALSEN   FR0012596468

SENSORION

(ALSEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Growth Paris
11/24/2020 11/25/2020 11/26/2020 11/27/2020 11/30/2020 Date
1.29(c) 1.27(c) 1.34(c) 1.465(c) 1.38 Last
49 116 29 898 65 912 532 494 270 618 Volume
-1.15% -1.55% +5.51% +9.33% -5.80% Change
More quotes
Financials
Sales 2020 5,85 M 6,98 M 6,98 M
Net income 2020 -19,9 M -23,7 M -23,7 M
Net Debt 2020 9,27 M 11,1 M 11,1 M
P/E ratio 2020 -4,18x
Yield 2020 -
Sales 2021 2,65 M 3,16 M 3,16 M
Net income 2021 -20,1 M -24,0 M -24,0 M
Net cash position 2021 10,3 M 12,3 M 12,3 M
P/E ratio 2021 -4,18x
Yield 2021 -
Capitalization 106 M 127 M 126 M
EV / Sales 2020 19,7x
EV / Sales 2021 36,1x
Nbr of Employees 24
Free-Float 80,1%
More Financials
Company
Sensorion specializes in the research and development of medicines for the treatment of inner ear disorders (dizziness or loss of balance, hearing problems, tinnitus, etc.). At the end of 2019, the company has a portfolio of 2 products in Phase II clinical development (SENS-111 for the treatment of acute attack of vertigo, and SENS-401 for the protective treatment of internal ear tissue in case of lesional attacks). 
More about the company
All news about SENSORION
11/20SENSORION : Hosting Key Opinion Leader Call with Dr. John Greinwald on Genetic H..
BU
11/18SENSORION : Balance of the liquidity contract to June 30, 2020. Read
PU
11/04SENSORION : Corporate presentation
PU
11/03SENSORION : announces attendance and a presentation at upcoming conferences. Rea..
PU
11/03SENSORION : Announces Attendance and a Presentation at Upcoming Conferences
BU
10/27SENSORION : and Novasep announce signature of a gene therapy product development..
PU
10/27SENSORION : and Novasep Announce Signature of a Gene Therapy Product Development..
BU
10/21SENSORION : reports 2020 first half results. Financial position strengthened wit..
PU
10/21SENSORION : Corporate presentation
PU
10/21SENSORION : reports 2020 first half results
BU
10/20SENSORION : Joins the EnterNext© PEA-PME 150 Index of Euronext Paris
BU
10/15SENSORION : Corporate presentation
PU
10/15SENSORION : obtains €3 million loans, including €2 million guaranteed by the Fre..
PU
10/15SENSORION : Obtains €3 Million Loans, Including €2 Million Guaranteed by the Fre..
BU
10/01SENSORION : Announces Attendance and Presentations at Upcoming Conferences
BU
More news
News in other languages on SENSORION
11/20SENSORION : organise une conférence téléphonique sur les pertes d'audition génét..
11/20SENSORION : organise une conférence téléphonique sur les pertes d'audition génét..
11/18SENSORION : Bilan semestriel du contrat de liquidité au 30 juin 2020. Lire
11/03SENSORION : participera et présentera lors de plusieurs conférences à venir
10/27Peur sur la reprise
More news
Chart SENSORION
Duration : Period :
Sensorion Technical Analysis Chart | ALSEN | FR0012596468 | MarketScreener
Technical analysis trends SENSORION
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 5,00 €
Last Close Price 1,38 €
Spread / Highest target 262%
Spread / Average Target 262%
Spread / Lowest Target 262%
EPS Revisions
Managers
NameTitle
Nawal Ouzren Chief Executive Officer & Director
Edwin Moses Chairman
Géraldine Honnet Chief Medical Officer
Chahra Louafi Director
Eric Forquenot de La Fortelle Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SENSORION73.37%134
MODERNA, INC.549.44%50 267
LONZA GROUP AG56.23%45 319
CELLTRION, INC.82.04%40 460
IQVIA HOLDINGS INC.9.26%32 365
SEAGEN INC.48.01%30 493